In silico identification and analysis of drug resistant mutants of ABL tyrosine kinase based on detrimental missense mutations

Current Signal Transduction Therapy

Volumn 6, Issue 3, 2011, Pages 396-404

  Rajasekaran, R ^a   Doss, C George Priya ^a   Prasad, G Arun ^a   Sethumadhavan, Rao ^a  

^a VIT UNIVERSITY   (India)

Author keywords

ABL tyrosine kinase; Docking; Flexibility; Imatinib; Missense mutation; Modeling

Indexed keywords

ABELSON KINASE; IMATINIB;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; COMPUTER MODEL; COMPUTER PROGRAM; CONFORMATIONAL TRANSITION; MISSENSE MUTATION; MOLECULAR DOCKING; POINT MUTATION; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; STRUCTURAL HOMOLOGY; SUPPORT VECTOR MACHINE;

EID: 80054886709     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436211797483903     Document Type: Article

References (48)

1. Cowan-Jacob SW, Fendrich G, Floersheimer A, et al. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D Biol Crystallogr 2007; 63: 80-93. (Pubitemid 46141483)
2. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758-766. (Pubitemid 30120840)
3. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95: 3498-505. (Pubitemid 30428483)
4. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80. (Pubitemid 32743979)
5. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472-475. (Pubitemid 34525335)
6. Hofmann WK, Jones LC, Lemp NA, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002; 99: 1860-862. (Pubitemid 34533064)
7. Von Bubnoff N, Schneller F, Peschel C, et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphiachromosome- positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487-91. (Pubitemid 34164296)
8. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014-18. (Pubitemid 34832631)
9. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-25. (Pubitemid 41039112)
10. Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000; 289: 1938-942.
11. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and Imatinib (STI-571). Cancer Res 2002; 62: 4236-243. (Pubitemid 34827278)
12. Drucker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-66.
13. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997; 23: 380-94. (Pubitemid 28123720)
14. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691-698. (Pubitemid 27473440)
15. Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002; 99: 10700-705.
16. Corbin AS, Buchdunger E, Pascal F, et al. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002; 277: 32214-219. (Pubitemid 34969036)
17. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-196. (Pubitemid 35331833)
18. Corbin AS, LaRosee P, Stoffregen EP, et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101: 4611-614 (Pubitemid 36857835)
19. Rajasekaran R, George Priya Doss C, Sudandiradoss C, et al. Effect of deleterious nsSNP on the HER2 receptor based on stability and binding affinity with herceptin: a computational approach. C R Biol 2008; 331: 409-17.
20. Boeckmann B, Bairoch A, Apweiler R, et al. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res 2003; 31: 365-70. (Pubitemid 36157284)
21. Yip YL, Famiglietti M, Gos A, Duek PD, et al. Annotating single amino acid polymorphisms in the UniProt/Swiss-Prot knowledgebase. Hum Mutat 2008; 29: 361-66. (Pubitemid 351364937)
22. Yip YL, Scheib H, Diemand AV, et al. The Swiss-Prot variant page and the ModSNP database: a resource for sequence and structure information on human protein variants. Hum Mutat 2004; 23: 464-70. (Pubitemid 38569219)
23. Berman HM, Westbrook J, Feng Z, et al.The Protein Data Bank. Nucleic Acids Res 2000; 28: 235-42. (Pubitemid 30047768)
24. Capriotti E, Fariselli P, Casadio R. I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res 2005; 33: 306-10.
25. Bava KA, Gromiha MM, Uedaira H, et al. ProTherm, version 4.0: thermodynamic database for proteins and mutants. Nucleic Acids Res 2004; 32: 120-21.
26. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 2003; 31: 3812-814. (Pubitemid 37442253)
27. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001; 11: 863-74. (Pubitemid 32447869)
28. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002; 30: 3894-900. (Pubitemid 35012462)
29. Cavallo A, Martin AC. Mapping SNPs to protein sequence and structure data Bioinformatics 2005; 21: 1443-450. (Pubitemid 40542699)
30. Lindahl E, Azuara C, Koehl P, Delarue M. NOMAD-Ref: visualization, deformation and refinement of macromolecular structures based on all-atom normal mode analysis. Nucleic Acids Res 2006; 34: 52-56.
31. Delarue M, Dumas P. On the use of low-frequency normal modes to enforce collective movements in refining macromolecular structural models. Proc Natl Acad Sci USA 2004; 101: 6957-962. (Pubitemid 38596425)
32. Sharma S, Ding F, Nie H, et al. iFold: a platform for interactive folding simulations of proteins. Bioinformatics 2006; 22: 2693-694. (Pubitemid 44642611)
33. Han JH, Kerrison N, Chothia C, Teichmann SA. Divergence of interdomain geometry in two domain proteins. Structure 2006; 14: 935-45.
34. Varfolomeev SD, Uporov IV, Fedorov EV. Bioinformatics and molecular modeling in chemical enzymology. Active sites of hydrolases. Biochemistry (Mosc) 2002; 67: 1099-108. (Pubitemid 35468951)
35. López G, Valencia A, Tress ML. firestar-prediction of functionally important residues using structural templates and alignment reliability. Nucleic Acids Res 2007; 35: 573-77.
36. Duhovny D, Nussinov R, Wolfson HJ. Efficient Unbound Docking of Rigid Molecules. In Gusfield et al., Ed. Proceedings of the second Workshop on Algorithms in Bioinformatics(WABI) Lecture Notes in Computer Science 2452, Springer Verlag, Rome, Italy, 2002; pp. 185-200.
37. Connolly ML. Solvent-accessible surfaces of proteins and nucleic acids. Science 1983; 221: 709-13.
38. Connolly ML Analytical molecular surface calculation. J. Appl. Cryst 1983; 16: 548-58.
39. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res 2005; 33: 363-67.
40. Zhang C, Vasmatzis G, Cornette JL, DeLisi C. Determination of atomic desolvation energies from the structures of crystallized proteins. J Mol Biol 1997; 267: 707-26. (Pubitemid 27170692)
41. Yuan Z, Bailey TL, Teasdale RD. Prediction of protein B-factor profiles. Proteins 2005; 58 : 905-12. (Pubitemid 40271255)
42. Ringe D, Petsko GA. Study of protein dynamics by X-ray diffraction. Methods Enzymol 1986; 131: 389-33.
43. Parthasarathy S, Murthy MR. Protein thermal stability: Insights from atomic displacement parameters (B values). Protein Eng 2000; 13: 9-13. (Pubitemid 30105572)
44. Carlson HA, McCammon JA. Accommodating protein flexibility in computational drug design. Mol. Pharmacol 2000; 57: 213-18. (Pubitemid 30084497)
45. Hinkle A, Tobacman LS. Folding and function of the troponin tail domain. Effects of cardiomyopathic troponin T mutations. J Biol Chem 2003; 278: 506-13. (Pubitemid 36043603)
46. Suhre K, Sanejouand YH. ElNémo: A normal mode web-server for protein movement analysis and the generation of templates for molecular replacement. Nucleic Acids Res 2004; 32: 610-14.
47. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242-249. (Pubitemid 47523141)
48. Soverini S, Colarossi S, Gnani A, et al. GIMEMA Working Party on Chronic Myeloid Leukemia. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12: 7374-379. (Pubitemid 46095411)